甲磺酸阿帕替尼治疗晚期肺癌不良反应的护理观察

扫码查看

原文链接

NETL
NSTL
万方数据
维普

中文摘要：目的研究60例晚期非小细胞肺癌患者在进行甲磺酸阿帕替尼治疗后的不良反应,并制定针对这些不良反应的护理方法 .方法选取2015年9月～2016年9月在浙江省肿瘤医院胸部肿瘤内科就诊并且接受治疗的非小细胞肺癌患者为研究对象,给予甲磺酸阿帕替尼片治疗,观察患者治疗过程中出现的不良反应.结果共有45例患者发生不良反应,不良反应发生率为75.00％.其中29例子患者发生皮疹,24例患者发生高血压,30例患者发生腹泻,21例患者出现恶心呕吐,5例患者出现蛋白尿,口腔黏膜炎7例,其他肝功能异常、血小板下降、咯血、乏力各出现2例.对各项不良反应进行针对性护理.结论晚期非小细胞肺癌患者用甲磺酸阿帕替尼进行治疗后出现不良反应,通过护理干预可以提高患者的生活质量.

外文标题：Nursing observation of adverse reactions of advanced lung cancer treated with Apa imatinib mesylate

外文摘要：Objective Study on 60 cases of advanced non-small cell lung cancer patients in the Apa imatinib mesylateadverse reactions after treatment , and to develop nursing methods for these adverse reactions. Methods Non-small cell lung cancer patients who were treated in our hospital from September 2015 to September 2016 were treated with Apa imatinib mesylate and observed the adverse reactions during the course of treatment. Results Adverse reactions occurred in 45 patients, and the incidence of adverse reactions was 75.00％.29 cases of patients with skin rash, 24 cases occurred in patients with hypertension, 30 cases of patients with diarrhea, nausea and vomiting occurred in 21 patients, 5 cases occurred in patients with proteinuria, 7 cases of patients with oral mucositis.Conclusion Non-small cell lung cancer patients had adverse reactions after treatment with Apa imatinib mesylate and nursing intervention can improve the quality of life of patients.

外文关键词：

Apa imatinib mesylateadvanced non-small cell lung cancer patientsadverse reactions

作者：

俞智敏、陈美华、张沂平、叶小红

展开 >

作者单位：

浙江省肿瘤医院 112病区,浙江杭州 310022

关键词：

甲磺酸阿帕替尼晚期非小细胞肺癌不良反应

出版年：

2017

DOI：